27 November 2024 NICE issues draft guidance for use of molnupiravir for treatment of COVID-19 Draft guidance for public consultation has been published by the National Institute for Health and Care Excellence (NICE).
6 November 2024 Relaunch of the Innovative Licensing and Access Pathway (ILAP) View the ILAP Statement of Policy Intent
9 September 2024 September 2024 decisions news release SMC advice on four new medicines The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday, July 8) published advice on four medicines.
24 July 2024 SMC publishes Collaborative Advice Documents for ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis.
8 July 2024 July 2024 decisions news release SMC advice on eight new medicines The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday, July 8) published advice on eight medicines.
20 June 2024 NICE issues final draft guidance on multiple technology appraisal (MTA), ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor– ivacaftor for treating cystic fibrosis. NICE issues final draft guidance on multiple technology appraisal (MTA), ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor– ivacaftor for treating cystic fibrosis.
